World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 94 10452 9813 998 953 386 33884

John F.R. Robertson publications per year

The chart shows the history of publications by John F.R. Robertson between 1986 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. John F.R. Robertson published across 40 years, from 1986 to 2025, averaging 11.4 papers a year. Output peaked at 43 publications in 2023. 27 of the 455 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 1986 to 2025. Vertical axis: number of publications, 0 to 43. Peak 43 publications in 2023. 1986: 1 publication 1987: 0 publications 1988: 3 publications 1989: 3 publications 1990: 4 publications 1991: 6 publications 1992: 4 publications 1993: 2 publications 1994: 6 publications 1995: 8 publications 1996: 5 publications 1997: 18 publications 1998: 8 publications 1999: 11 publications 2000: 9 publications 2001: 22 publications 2002: 17 publications 2003: 14 publications 2004: 17 publications 2005: 12 publications 2006: 14 publications 2007: 24 publications 2008: 12 publications 2009: 14 publications 2010: 27 publications 2011: 15 publications 2012: 12 publications 2013: 6 publications 2014: 11 publications 2015: 8 publications 2016: 9 publications 2017: 13 publications 2018: 12 publications 2019: 6 publications 2020: 13 publications 2021: 14 publications 2022: 5 publications 2023: 43 publications 2024: 10 publications 2025: 17 publications
1986 2025

455 publications in total across all disciplines

View publications per year as a table
John F.R. Robertson: publications per year, 1986 to 2025
Year Publications
1986 1
1987 0
1988 3
1989 3
1990 4
1991 6
1992 4
1993 2
1994 6
1995 8
1996 5
1997 18
1998 8
1999 11
2000 9
2001 22
2002 17
2003 14
2004 17
2005 12
2006 14
2007 24
2008 12
2009 14
2010 27
2011 15
2012 12
2013 6
2014 11
2015 8
2016 9
2017 13
2018 12
2019 6
2020 13
2021 14
2022 5
2023 43
2024 10
2025 17
Total 455
Download as CSV

John F.R. Robertson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John F.R. Robertson sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 381–400 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 386 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861 386
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

John F.R. Robertson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John F.R. Robertson sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 94–95 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808 94
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

John F.R. Robertson is affiliated with the University of Nottingham in the United Kingdom. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, contributing notably to the areas of Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Surgery.

Their work focuses on several key topics including:

  • Estrogen and related hormone effects
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Global Cancer Incidence and Screening
  • Cancer Treatment and Pharmacology
  • Cancer survivorship and care

Among recent publications, the following papers reflect some of the contributions made:

  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials" (2021), published in The Lancet Oncology
  • "Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial" (2020), published in The Lancet Oncology
  • "ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials" (2020), published in Clinical Cancer Research
  • "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials" (2023), published in The Lancet
  • "Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic" (2020), published in npj Breast Cancer

Frequently collaborating with other researchers, John F.R. Robertson has co-authored numerous works alongside:

  • Judith M. Bliss
  • Mitch Dowsett
  • Lucy Kilburn
  • Holly Tovey
  • Maggie C.U. Cheang

Their publications have appeared consistently in various scientific venues, with multiple contributions to:

  • Cancer Research
  • European Journal of Surgical Oncology
  • Clinical Cancer Research
  • The Lancet
  • BMJ Open Quality

Best Publications

  • Prognostic markers in triple-negative breast cancer

    Emad A. Rakha;Maysa E. El-Sayed;Andrew R. Green;Andrew H. S. Lee

  • Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

    J Bonneterre;B Thurlimann;J Robertson;M Krzakowski

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

    Anthony Howell;John F R Robertson;J Quaresma Albano;A Aschermannova

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

    Dalia M. Abd El-Rehim;Graham Ball;Sarah E. Pinder;Emad Rakha

  • Expression of luminal and basal cytokeratins in human breast carcinoma

    Dalia M Abd El-Rehim;Sarah E Pinder;Claire E Paish;J Bell

  • Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

    Jacques Bonneterre;Aman Buzdar;Jean‐Marc A. Nabholtz;John F. R. Robertson

  • Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

    Stephen Chia;William Gradishar;Louis Mauriac;Jose Bines

  • Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

    John F.R. Robertson;Igor M. Bondarenko;Ekaterina Trishkina;Mikhail Dvorkin

  • Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

    Anthony Howell;John F R Robertson;Paul Abram;Mikhail R Lichinitser

  • Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

    Anthony Howell;John Robertson

  • Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

    E A Rakha;T C Putti;D M Abd El-Rehim;C Paish

  • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.

    John F.R. Robertson;C. Kent Osborne;Anthony Howell;Stephen E. Jones

  • Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor–Positive Phenotype

    Emad A. Rakha;Maysa E. El-Sayed;Andrew R. Green;E. Claire Paish

  • Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.

    Emad A Rakha;Richard W G Boyce;Dalia Abd El-Rehim;Thomas Kurien

  • Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer

    Julia Margaret Wendy Gee;J. F. Robertson;E. Gutteridge;I. O. Ellis

  • Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

    John F.R. Robertson;Antonio Llombart-Cussac;Janusz Rolski;David Feltl

  • Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

    N. Bouzubar;K. J. Walker;K. Griffiths;I. O. Ellis

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

Frequent Co-Authors

Ian O. Ellis
Ian O. Ellis University of Nottingham
Robert Ian Nicholson
Robert Ian Nicholson Cardiff University
Roger W. Blamey
Roger W. Blamey Nottingham City Hospital
Julia Margaret Wendy Gee
Julia Margaret Wendy Gee Cardiff University
Sarah E Pinder
Sarah E Pinder King's College London
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Anthony Howell
Anthony Howell University of Manchester
C.W. Elston
C.W. Elston University of Nottingham
Matthew J. Ellis
Matthew J. Ellis Baylor College of Medicine
Andrew Evans
Andrew Evans University of Dundee

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine goes beyond becoming a doctor. The healthcare field in the U.S. offers a variety of related degree options and career pathways, many of which can be pursued online for added flexibility. For those interested in nursing, some nursing schools that don't require teas test can provide a more accessible route into the nursing profession.

If you are more interested in management or organizational roles, consider an online healthcare administration degree. This can open doors to leadership positions in hospitals, clinics, and public health organizations.

RNs looking to advance their careers may benefit from adn to np programs online, which provide flexible bridge programs to help nurses become nurse practitioners faster. Additionally, those passionate about wellness and nutrition can earn an online bs in nutrition to explore roles in dietetics, health coaching, and education.

Exploring these related online degrees can help you tailor a healthcare career that fits your strengths and interests, all while balancing work and study commitments.

Best Scientists Citing John F.R. Robertson

Trending Scientists

Recently Published Articles